These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 22262156)

  • 1. Anthropometric measures and risk of ovarian cancer among BRCA1 and BRCA2 mutation carriers.
    McGee J; Kotsopoulos J; Lubinski J; Lynch HT; Rosen B; Tung N; Kim-Sing C; Karlan B; Foulkes WD; Ainsworth P; Ghadirian P; Senter L; Eisen A; Sun P; Narod SA;
    Obesity (Silver Spring); 2012 Jun; 20(6):1288-92. PubMed ID: 22262156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast-feeding and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Jernström H; Lubinski J; Lynch HT; Ghadirian P; Neuhausen S; Isaacs C; Weber BL; Horsman D; Rosen B; Foulkes WD; Friedman E; Gershoni-Baruch R; Ainsworth P; Daly M; Garber J; Olsson H; Sun P; Narod SA
    J Natl Cancer Inst; 2004 Jul; 96(14):1094-8. PubMed ID: 15265971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
    Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
    J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Neuhausen SL; Lynch HT; Rosen B; Ainsworth P; Moller P; Ghadirian P; Isaacs C; Karlan B; Sun P; Narod SA
    Gynecol Oncol; 2006 Jan; 100(1):83-8. PubMed ID: 16137751
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Parity and the risk of breast and ovarian cancer in BRCA1 and BRCA2 mutation carriers.
    Milne RL; Osorio A; Ramón y Cajal T; Baiget M; Lasa A; Diaz-Rubio E; de la Hoya M; Caldés T; Teulé A; Lázaro C; Blanco I; Balmaña J; Sánchez-Ollé G; Vega A; Blanco A; Chirivella I; Esteban Cardeñosa E; Durán M; Velasco E; Martínez de Dueñas E; Tejada MI; Miramar MD; Calvo MT; Guillén-Ponce C; Salazar R; San Román C; Urioste M; Benítez J
    Breast Cancer Res Treat; 2010 Jan; 119(1):221-32. PubMed ID: 19370414
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation.
    Modan B; Hartge P; Hirsh-Yechezkel G; Chetrit A; Lubin F; Beller U; Ben-Baruch G; Fishman A; Menczer J; Struewing JP; Tucker MA; Wacholder S;
    N Engl J Med; 2001 Jul; 345(4):235-40. PubMed ID: 11474660
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Age at first birth and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Klijn J; Ghadirian P; Neuhausen SL; Kim-Sing C; Foulkes WD; Moller P; Isaacs C; Domchek S; Randall S; Offit K; Tung N; Ainsworth P; Gershoni-Baruch R; Eisen A; Daly M; Karlan B; Saal HM; Couch F; Pasini B; Wagner T; Friedman E; Rennert G; Eng C; Weitzel J; Sun P; Narod SA; ; Garber J; Osborne M; Fishman D; McLennan J; McKinnon W; Merajver S; Olsson H; Provencher D; Pasche B; Evans G; Meschino WS; Lemire E; Chudley A; Rayson D; Bellati C
    Breast Cancer Res Treat; 2007 Oct; 105(2):221-8. PubMed ID: 17245541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Age at menarche and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.
    Kotsopoulos J; Lubinski J; Lynch HT; Neuhausen SL; Ghadirian P; Isaacs C; Weber B; Kim-Sing C; Foulkes WD; Gershoni-Baruch R; Ainsworth P; Friedman E; Daly M; Garber JE; Karlan B; Olopade OI; Tung N; Saal HM; Eisen A; Osborne M; Olsson H; Gilchrist D; Sun P; Narod SA
    Cancer Causes Control; 2005 Aug; 16(6):667-74. PubMed ID: 16049805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors for carcinoma of the fallopian tube in women with and without a germline BRCA mutation.
    Vicus D; Finch A; Rosen B; Fan I; Bradley L; Cass I; Sun P; Karlan B; McLaughlin J; Narod SA;
    Gynecol Oncol; 2010 Aug; 118(2):155-9. PubMed ID: 20452659
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.
    Satagopan JM; Boyd J; Kauff ND; Robson M; Scheuer L; Narod S; Offit K
    Clin Cancer Res; 2002 Dec; 8(12):3776-81. PubMed ID: 12473589
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.
    Casey MJ; Synder C; Bewtra C; Narod SA; Watson P; Lynch HT
    Gynecol Oncol; 2005 May; 97(2):457-67. PubMed ID: 15863145
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Body weight and risk of breast cancer in BRCA1/2 mutation carriers.
    Manders P; Pijpe A; Hooning MJ; Kluijt I; Vasen HF; Hoogerbrugge N; van Asperen CJ; Meijers-Heijboer H; Ausems MG; van Os TA; Gomez-Garcia EB; Brohet RM; ; van Leeuwen FE; Rookus MA
    Breast Cancer Res Treat; 2011 Feb; 126(1):193-202. PubMed ID: 20730487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Appendectomy and cancer risk in Jewish BRCA1 and BRCA2 mutation carriers.
    Bernholtz S; Jakobson-Setton A; Korach J; Ben Baruch G; Laitman Y; Friedman E
    Breast Cancer Res Treat; 2012 Feb; 131(3):981-5. PubMed ID: 21984204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain.
    Milne RL; Osorio A; Cajal TR; Vega A; Llort G; de la Hoya M; Díez O; Alonso MC; Lazaro C; Blanco I; Sánchez-de-Abajo A; Caldés T; Blanco A; Graña B; Durán M; Velasco E; Chirivella I; Cardeñosa EE; Tejada MI; Beristain E; Miramar MD; Calvo MT; Martínez E; Guillén C; Salazar R; San Román C; Antoniou AC; Urioste M; Benítez J
    Clin Cancer Res; 2008 May; 14(9):2861-9. PubMed ID: 18451254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families.
    Antoniou AC; Durocher F; Smith P; Simard J; Easton DF;
    Breast Cancer Res; 2006; 8(1):R3. PubMed ID: 16417652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BRCA1 and BRCA2 mutation prevalence and clinical characteristics of a population-based series of ovarian cancer cases from Denmark.
    Soegaard M; Kjaer SK; Cox M; Wozniak E; Høgdall E; Høgdall C; Blaakaer J; Jacobs IJ; Gayther SA; Ramus SJ
    Clin Cancer Res; 2008 Jun; 14(12):3761-7. PubMed ID: 18559594
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.
    Casey MJ; Bewtra C; Hoehne LL; Tatpati AD; Lynch HT; Watson P
    Gynecol Oncol; 2000 Sep; 78(3 Pt 1):278-87. PubMed ID: 10985881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers.
    Metcalfe KA; Lynch HT; Ghadirian P; Tung N; Olivotto IA; Foulkes WD; Warner E; Olopade O; Eisen A; Weber B; McLennan J; Sun P; Narod SA
    Gynecol Oncol; 2005 Jan; 96(1):222-6. PubMed ID: 15589605
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers.
    Rebbeck TR
    J Clin Oncol; 2000 Nov; 18(21 Suppl):100S-3S. PubMed ID: 11060335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
    Wang-Gohrke S; Weikel W; Risch H; Vesprini D; Abrahamson J; Lerman C; Godwin A; Moslehi R; Olipade O; Brunet JS; Stickeler E; Kieback DG; Kreienberg R; Weber B; Narod SA; Runnebaum IB
    Br J Cancer; 1999 Sep; 81(1):179-83. PubMed ID: 10487631
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.